Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals (ALNY) EVP Chief R&D Pushkal Garg reported PSU vesting and related share sales. On 10/01/2025, he acquired 3,108 and 2,851 common shares at $0.00 upon vesting tied to the company publicly reporting the initiation of Phase 3 clinical studies, as determined by the Board’s PC&C Committee.
On 10/02/2025, shares were sold automatically to cover taxes from the PSU settlements at disclosed weighted average prices by tranche; additional sales on 10/03/2025 were made under a Rule 10b5‑1(c) trading plan adopted on 09/11/2024. After these transactions, direct holdings were 20,221 shares, with 431 held via a managed account and 250 held in a trust.
Alnylam Pharmaceuticals reported a material event on an Form 8-K that discloses a Credit Agreement dated September 30, 2025 among Alnylam, the lenders party to the agreement, and Bank of America, N.A. acting as Administrative Agent. The filing references an interactive cover page data file embedded within the Inline XBRL document and is signed by Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer. No loan amounts, interest terms, covenants, maturity dates, or other economic details are included in the provided text.
Alnylam Pharmaceuticals (ALNY) filed a Form 144 notifying of a proposed sale of 3,022 common shares with an aggregate market value of $1,362,922.00. The shares are to be sold through UBS Financial Services, Inc. on or about 10/03/2025. The filer states these shares were acquired as PSUs from the issuer on 10/01/2025. The notice also discloses a prior sale by Pushkal Garg of 1,455 shares on 08/19/2025 for gross proceeds of $666,989.17. The filer attests there is no undisclosed material adverse information.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form 3 filed for Bryan Supran, who is identified as Executive Vice President, Chief Legal Officer and Secretary. The event date requiring the statement is 09/15/2025. The filing states that no securities are beneficially owned by the reporting person and attaches Exhibit 24 (Power of Attorney). The form is signed by an attorney-in-fact on behalf of Mr. Supran on 09/22/2025.
Colleen F. Reitan, an Alnylam Pharmaceuticals director, reported multiple transactions on 09/09/2025 under a Rule 10b5-1(c) plan adopted June 10, 2025. She exercised a stock option to buy 18,000 shares at an exercise price of $100.65 and subsequently sold incremental blocks of common stock in multiple transactions at weighted-average prices ranging from $456.93 to $479.90. Following the reported trades, she directly beneficially owns 775 shares and holds options covering 18,000 shares exercisable through 06/01/2028. The filing was signed by her attorney-in-fact on 09/11/2025.
Alnylam Pharmaceuticals, Inc. filed an 8-K reporting a material event related to a Convertible Note Offering. The filing references press releases issued on September 8, 2025 and September 9, 2025
The submission also notes inclusion of the cover page interactive data file in Inline XBRL and is signed by Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer. The filing does not disclose terms, amounts, or use of proceeds for the convertible notes within the provided text.
Alnylam Pharmaceuticals (ALNY) notice reports a proposed sale of 18,000 shares of common stock through UBS Financial Services on the NASDAQ, with an aggregate market value of $8,300,070.00 and 131,079,015 shares outstanding. The securities were acquired and are proposed to be sold on 09/09/2025 via exercise of stock options from the issuer, with cash payment recorded. The filer reports no securities sold in the past three months. The form includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption if applicable.
Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals (ALNY), reported multiple open-market sales of Company common stock on 08/29/2025 executed under a Rule 10b5-1 trading plan. The filings show six separate sale transactions totaling 3,474 shares, with weighted average sale prices reported in ranges from approximately $445.32 to $452.54 per share. Following these transactions the reporting person’s beneficial ownership is reported as 25,992 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Tanguler and includes explanatory notes that each reported price is a weighted average of multiple executions within the stated ranges.
Form 144 filing for Alnylam Pharmaceuticals (ALNY) discloses a proposed sale of 3,474 shares of Common stock through UBS Financial Services on NASDAQ with an aggregate market value of $1,571,012 and 131,079,015 shares outstanding. The securities were acquired as performance stock units: 1,673 shares on 06/24/2024 and 1,801 shares on 04/26/2023, with payment dates matching acquisition dates. The filer reports Nothing to Report for securities sold in the past three months and includes the customary representation that they do not possess undisclosed material adverse information. The notice is procedural under Rule 144 to report an intended sale.
Pushkal Garg, Executive Vice President & Chief R&D Officer of Alnylam Pharmaceuticals (ALNY), reported transactions on Form 4 showing issued and subsequent sales of common stock tied to performance-based awards and a Rule 10b5-1 plan.
On 08/15/2025, 2,851 shares were issued upon vesting of 30% of a performance-based stock unit awarded 03/01/2024 after the company met a clinical milestone. Between 08/18/2025 and 08/19/2025 the reporting person sold multiple tranches of shares under a previously adopted 10b5-1 trading plan, at weighted-average prices ranging from about $447.98 to $461.74. Following these transactions, Garg directly owned 20,221 shares and indirectly held 431 shares via a managed account and 250 shares in a trust.